tranexamic acid has been researched along with Myocardial Infarction in 31 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Objective To summarize cases of acute myocardial infarction (AMI) after tranexamic acid (TXA) administration." | 9.05 | Acute Myocardial Infarction After Tranexamic Acid: Review of Published Case Reports. ( Shao, K; Yao, YT; Yuan, X, 2020) |
| "Tranexamic acid is an antifibrinolytic drug that is widely used during surgery, but there are concerns about its thromboembolic effects." | 7.01 | Prophylactic intravenous tranexamic acid and thromboembolism in non-cardiac surgery: a systematic review, meta-analysis and trial sequential analysis. ( Cheah, S; Cheong, CC; Mong, SXY; Ng, KT; Tsan, SEH; Viknaswaran, NL; Wang, CY, 2023) |
| " The purpose of this study was to determine if TXA is safe to use in patients with a history of CAD or coronary stents." | 5.62 | Tranexamic Acid Is Safe in Patients with a History of Coronary Artery Disease Undergoing Total Joint Arthroplasty. ( Rozell, JC; Schwarzkopf, R; Sharan, M; Tang, A; Waren, D; Zak, SG, 2021) |
| "The contribution of fibrinolysis to postoperative bleeding after cardiopulmonary bypass led to routine use of tranexamic acid, a potent antifibrinolytic drug, for a period of time." | 5.07 | Tranexamic acid (Cyklokapron) is not necessary to reduce blood loss after coronary artery bypass operations. ( Abdelnoor, M; Am Holen, E; Ovrum, E; Oystese, R; Ringdal, ML, 1993) |
| "Objective To summarize cases of acute myocardial infarction (AMI) after tranexamic acid (TXA) administration." | 5.05 | Acute Myocardial Infarction After Tranexamic Acid: Review of Published Case Reports. ( Shao, K; Yao, YT; Yuan, X, 2020) |
| " A combination of aprotinin with tranexamic acid may be effective in preventing or delaying rebleeding after rupture of an intracerebral aneurysm; the addition of aprotinin seems to decrease the incidence of delayed cerebral vasospasm and ischaemic complications which are sometimes noted when tranexamic acid alone is used." | 4.77 | Clinical application of inhibitors of fibrinolysis. ( Verstraete, M, 1985) |
| " Tranexamic acid (TA), an anti-fibrinolytic agent, has been shown to reduce peri-operative blood loss without increasing the risk of myocardial infarction (MI); however, no large study has examined the association between TA treatment and post-CABG myonecrosis." | 3.85 | Association between CK-MB Area Under the Curve and Tranexamic Acid Utilization in Patients Undergoing Coronary Artery Bypass Surgery. ( Alexander, JH; Carrier, M; Lopes, RD; Merrill, PD; Podgoreanu, M; Tardif, JC; van Diepen, S, 2017) |
| "The case report illustrates an acute myocardial infarction (MI) in a 41-year-old hypertensive woman possibly because of an intake of a combination of tranexamic acid and mefenamic acid for dysmenorrhoea and menorrhagia." | 3.79 | Acute MI in a young hypertensive woman: could it be due to tranexamic acid? ( Gupta, PN; Mullamalla, UR; Sabin, P; Vellappan, P, 2013) |
| "Factor VIII:C, epsilon amino-caproic acid or tranexamic acid are prophylactic agents used in preventing hemorrhage pre-operatively in patients with hemophilia A." | 3.75 | Acute myocardial infarction in a patient with hemophilia A and factor V Leiden mutation. ( Günaldi, M; Helvaci, A; Kiskaç, M; Küçükkaya, RD; Yildirim, ND, 2009) |
| " The ongoing trials create six new comparisons: tranexamic acid (tablet + injection) versus placebo; intravenous tranexamic acid versus oral tranexamic acid; topical tranexamic acid versus oral tranexamic acid; different intravenous tranexamic acid dosing regimes; topical tranexamic acid versus topical fibrin glue; and fibrinogen (injection) versus placebo." | 3.01 | Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint replacement for hip, pelvic and long bone fractures. ( Brunskill, SJ; Champaneria, R; Dorée, C; Estcourt, LJ; Geneen, LJ; Gibbs, VN; Novak, A; Palmer, AJ; Raval, P, 2023) |
| "Tranexamic acid is an antifibrinolytic drug that is widely used during surgery, but there are concerns about its thromboembolic effects." | 3.01 | Prophylactic intravenous tranexamic acid and thromboembolism in non-cardiac surgery: a systematic review, meta-analysis and trial sequential analysis. ( Cheah, S; Cheong, CC; Mong, SXY; Ng, KT; Tsan, SEH; Viknaswaran, NL; Wang, CY, 2023) |
| "Venous thromboembolic events (deep vein thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of 5952 vs 26 [0·4%] of 5977; RR 1·85; 95% CI 1·15 to 2·98)." | 2.94 | Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. ( , 2020) |
| " To date, the most efficacious dosing protocol in this setting has not yet been ascertained." | 1.72 | No Difference in Blood Loss and Risk of Transfusion Between Patients Treated with One or Two Doses of Intravenous Tranexamic Acid After Simultaneous Bilateral TKA. ( Bugbee, WD; Copp, SN; Evans, AS; Ezzet, KA; McCauley, JC; Rosen, AS; Walker, RH; Wilde, JM, 2022) |
| " The purpose of this study was to determine if TXA is safe to use in patients with a history of CAD or coronary stents." | 1.62 | Tranexamic Acid Is Safe in Patients with a History of Coronary Artery Disease Undergoing Total Joint Arthroplasty. ( Rozell, JC; Schwarzkopf, R; Sharan, M; Tang, A; Waren, D; Zak, SG, 2021) |
| "Tranexamic acid was effective in reducing the need for blood transfusions while not increasing the risk of complications, including thromboembolic events and renal failure." | 1.40 | Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. ( Boettner, F; Danninger, T; Mazumdar, M; Memtsoudis, SG; Opperer, M; Poeran, J; Rasul, R; Suzuki, S, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.23) | 18.7374 |
| 1990's | 3 (9.68) | 18.2507 |
| 2000's | 10 (32.26) | 29.6817 |
| 2010's | 9 (29.03) | 24.3611 |
| 2020's | 8 (25.81) | 2.80 |
| Authors | Studies |
|---|---|
| Wilde, JM | 1 |
| Copp, SN | 1 |
| Ezzet, KA | 1 |
| Rosen, AS | 1 |
| Walker, RH | 1 |
| McCauley, JC | 1 |
| Evans, AS | 1 |
| Bugbee, WD | 1 |
| Zhong, H | 1 |
| Poeran, J | 2 |
| Liu, J | 1 |
| Illescas, A | 1 |
| Cozowicz, C | 1 |
| Memtsoudis, SG | 2 |
| Lynham, R | 1 |
| Preissler, S | 1 |
| Lightfoot, NJ | 1 |
| Coates, J | 1 |
| Gibbs, VN | 1 |
| Geneen, LJ | 1 |
| Champaneria, R | 1 |
| Raval, P | 1 |
| Dorée, C | 1 |
| Brunskill, SJ | 1 |
| Novak, A | 1 |
| Palmer, AJ | 1 |
| Estcourt, LJ | 1 |
| Tsan, SEH | 1 |
| Viknaswaran, NL | 1 |
| Cheong, CC | 1 |
| Cheah, S | 1 |
| Ng, KT | 1 |
| Mong, SXY | 1 |
| Wang, CY | 1 |
| Yao, YT | 1 |
| Yuan, X | 1 |
| Shao, K | 1 |
| Zak, SG | 1 |
| Tang, A | 1 |
| Sharan, M | 1 |
| Waren, D | 1 |
| Rozell, JC | 1 |
| Schwarzkopf, R | 1 |
| Myles, PS | 2 |
| Smith, JA | 2 |
| Kasza, J | 2 |
| Silbert, B | 2 |
| Jayarajah, M | 2 |
| Painter, T | 2 |
| Cooper, DJ | 2 |
| Marasco, S | 2 |
| McNeil, J | 2 |
| Bussières, JS | 2 |
| McGuinness, S | 2 |
| Chan, MTV | 2 |
| Wallace, S | 2 |
| Forbes, A | 2 |
| Byrne, K | 1 |
| Landoni, G | 1 |
| Gupta, PN | 1 |
| Mullamalla, UR | 1 |
| Sabin, P | 1 |
| Vellappan, P | 1 |
| Roberts, I | 2 |
| Rasul, R | 1 |
| Suzuki, S | 1 |
| Danninger, T | 1 |
| Mazumdar, M | 1 |
| Opperer, M | 1 |
| Boettner, F | 1 |
| Sun, X | 1 |
| Dong, Q | 1 |
| Zhang, YG | 1 |
| van Diepen, S | 1 |
| Merrill, PD | 1 |
| Carrier, M | 1 |
| Tardif, JC | 1 |
| Podgoreanu, M | 1 |
| Alexander, JH | 1 |
| Lopes, RD | 1 |
| Dietrich, W | 1 |
| Spannagl, M | 1 |
| Boehm, J | 1 |
| Hauner, K | 1 |
| Braun, S | 1 |
| Schuster, T | 1 |
| Busley, R | 1 |
| Henry, D | 1 |
| Carless, P | 1 |
| Fergusson, D | 2 |
| Laupacis, A | 1 |
| Amissah-Arthur, KN | 1 |
| Groppe, M | 1 |
| Scotcher, S | 1 |
| Günaldi, M | 1 |
| Helvaci, A | 1 |
| Yildirim, ND | 1 |
| Kiskaç, M | 1 |
| Küçükkaya, RD | 1 |
| Ker, K | 1 |
| Edwards, P | 1 |
| Perel, P | 1 |
| Shakur, H | 1 |
| Hutton, B | 1 |
| Joseph, L | 1 |
| Mazer, CD | 1 |
| Shapiro, S | 1 |
| Tinmouth, A | 1 |
| Iacobellis, G | 2 |
| Mangano, DT | 1 |
| Tudor, IC | 1 |
| Dietzel, C | 1 |
| Sirker, A | 1 |
| Malik, N | 1 |
| Bellamy, M | 1 |
| Laffan, MA | 1 |
| Ovrum, E | 1 |
| Am Holen, E | 1 |
| Abdelnoor, M | 1 |
| Oystese, R | 1 |
| Ringdal, ML | 1 |
| Castelli, R | 1 |
| Cicardi, M | 1 |
| Gardinali, M | 1 |
| Zingale, LC | 1 |
| Savi, C | 1 |
| Munari, M | 1 |
| Agostoni, A | 1 |
| Levi, M | 1 |
| Cromheecke, ME | 1 |
| de Jonge, E | 1 |
| Prins, MH | 1 |
| de Mol, BJ | 1 |
| Briët, E | 1 |
| Büller, HR | 1 |
| Lefebvre, JM | 1 |
| Qanadli, SD | 1 |
| Kacher, S | 1 |
| Aberkane, L | 1 |
| Rigaud, M | 1 |
| Lacombe, P | 1 |
| Rocha, P | 1 |
| Ruel, MA | 1 |
| Wang, F | 1 |
| Bourke, ME | 1 |
| Dupuis, JY | 1 |
| Robblee, JA | 1 |
| Keon, WJ | 1 |
| Rubens, FD | 1 |
| Mekontso-Dessap, A | 1 |
| Collet, JP | 1 |
| Lebrun-Vignes, B | 1 |
| Soubrié, C | 1 |
| Thomas, D | 1 |
| Montalescot, G | 1 |
| Verstraete, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Precise Application of Topical Tranexamic Acid to Enhance Endoscopic Hemostasis for Peptic Ulcer Bleeding: A Randomized Controlled Study[NCT05248321] | 60 participants (Actual) | Interventional | 2022-03-24 | Completed | |||
| Tranexamic Acid for the Treatment of Gastrointestinal Haemorrhage: an International Randomised, Double Blind Placebo Controlled Trial[NCT01658124] | Phase 3 | 12,009 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| The Use of Tranexamic Acid to Reduce the Need for Transfusion 1 Week Post-operatively for Hemiarthroplasty or Intramedullary Nailing Needed to Correct Acute Hip Fractures[NCT02947529] | Phase 4 | 113 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| Single Centre Randomised Controlled Trial to Assess the Effect of the Addition of Twenty-four Hours of Oral Tranexamic Acid Post-operatively to a Single Intra-operative Intravenous Dose of Tranexamic Acid on Calculated Blood Loss Following Primary Hip and[NCT03690037] | Phase 4 | 1,089 participants (Actual) | Interventional | 2016-07-07 | Completed | ||
| Prospective Randomized Study Comparing Topical Versus Intravenous Tranexamic Acid in Anterior Total Hip Arthroplasty[NCT03359525] | Phase 4 | 114 participants (Anticipated) | Interventional | 2017-07-01 | Recruiting | ||
| The Effect of Tranexamic Acid (TXA) on Blood Loss and Transfusion Rates in Burn Wound Surgery - A Randomized, Double-Blinded Placebo-Controlled Trial[NCT02753816] | 25 participants (Actual) | Interventional | 2016-04-30 | Terminated (stopped due to Study enrollment and goals unable to be reached.) | |||
| Local Injection of Tranexamic Acid May Reduce Bleeding, Injection Pain, and Other Post-op Complications During Mohs Micrographic Surgery[NCT04630886] | Early Phase 1 | 200 participants (Anticipated) | Interventional | 2021-06-16 | Enrolling by invitation | ||
| The Influence of High-Dose Aprotinin and Tranexamic Acid on Bleeding Tendency and Allogeneic Blood Transfusion in Patients Undergoing Primary Aortic Valve Replacement or Coronary Artery Revascularization[NCT00396760] | Phase 3 | 220 participants | Interventional | 2005-01-31 | Active, not recruiting | ||
| Tranexamic Acid's Effects in Patients Undergoing Laparoscopic Radical Prostatectomy: a Randomized, Double-blind, Placebo-controlled Trial[NCT05816668] | Phase 3 | 122 participants (Anticipated) | Interventional | 2023-04-30 | Not yet recruiting | ||
| The Use of Tranexamic Acid to Reduce Perioperative Blood Loss During High Risk Spine Fusion Surgery[NCT01728636] | Phase 2 | 61 participants (Actual) | Interventional | 2013-01-15 | Completed | ||
| Prophylactic Use of Tranexamic Acid for Preventing Postpartum Hemorrhage: A Randomized, Double-blinded, Placebo-controlled Pilot Trial[NCT03069859] | Phase 2 | 31 participants (Actual) | Interventional | 2018-03-06 | Active, not recruiting | ||
| IV Tranexamic Acid Prior to Hysterectomy for Reduction of Intraoperative Blood Loss: A Randomized Placebo-Controlled Trial[NCT02911831] | Early Phase 1 | 71 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Evaluating the Use of Tranexamic Acid (TXA) in Total Joint Arthroplasty[NCT03825939] | Phase 4 | 52 participants (Actual) | Interventional | 2015-04-21 | Terminated (stopped due to Lack of patient enrollment due to only one surgeon that was enrolling.) | ||
| A Randomized Comparison of Two Doses of Tranexamic Acid in Open-Heart Surgery[NCT04996368] | 120 participants (Actual) | Interventional | 2022-02-01 | Completed | |||
| A Randomized Control Trial Evaluating the Use of Topical Tranexamic Acid in Bilateral Breast Reduction Surgery to Prevent Bleeding Complications[NCT04918576] | Phase 3 | 106 participants (Anticipated) | Interventional | 2022-08-31 | Not yet recruiting | ||
| Effects of Tranexamic Acid for Alloplastic Breast Reconstruction: A Randomized Control Trial[NCT04918589] | Phase 3 | 106 participants (Anticipated) | Interventional | 2022-08-31 | Not yet recruiting | ||
| The Effect of Tranexamic Acid (TXA) on Blood Loss in Burn Surgery - A Randomized, Double-Blinded Placebo-Controlled Trial[NCT03113253] | Phase 4 | 121 participants (Actual) | Interventional | 2016-09-22 | Active, not recruiting | ||
| Influence of Elevated Baseline Serum Creatinine and Body Composition on Acute Kidney Injury in Cardiac Surgery - The InCreAS Trial[NCT02598271] | 200 participants (Actual) | Observational | 2016-10-31 | Completed | |||
| The Effect of Low Dose Corticosteroids on Perioperative Markers of Thrombosis and Fibrinolysis in Total Knee Arthroplasty[NCT01815918] | Phase 4 | 60 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| Outcome Impact of Different Tranexamic Acid Regimen in Cardiac Surgery With Cardiopulmonary Bypass (the OPTIMAL Study)[NCT03782350] | Phase 4 | 3,079 participants (Actual) | Interventional | 2018-12-26 | Completed | ||
| Efficacy in Controlling Bleeding Post-coronary Bypass Surgery Using Combination of Local Application of Tranexamic Acid and Intravenous Tranexamic Compared to Intravenous Tranexamic Acid Alone. A Randomized Controlled Trial[NCT01600599] | 40 participants (Actual) | Interventional | 2011-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To determine the impact of perioperative administration of Tranexamic Acid on transfusion rates in major burn surgeries. (NCT02753816)
Timeframe: First burn surgery to hospital discharge
| Intervention | Patients with 1 or more transfusions (Number) |
|---|---|
| Tranexamic Acid | 2 |
| Placebo | 3 |
To determine the impact of Tranexamic Acid on total hospital length of stay by comparing the hospital admission date and the hospital discharge date. This determination will take into account current burn size and location, procedures performed and their effect on wound healing and skin graft survival. (NCT02753816)
Timeframe: Hospital admission to hospital discharge
| Intervention | Days (Median) |
|---|---|
| Tranexamic Acid | 23 |
| Placebo | 9 |
To determine the impact of perioperative administration of Tranexamic Acid on blood loss in major burn surgeries. (NCT02753816)
Timeframe: Intraoperative, average 122 minutes
| Intervention | mL (Median) |
|---|---|
| Tranexamic Acid | 100 |
| Placebo | 325 |
Total additional blood products (fresh frozen plasma, cryoprecipitate, and platelets) transfused in the perioperative period measured in units. (NCT01728636)
Timeframe: 24 hours after skin incision
| Intervention | Units (Mean) |
|---|---|
| Tranexamic Acid | 1 |
| Placebo | 2 |
Estimated Intraoperative blood loss in milliliters (mLs) (NCT01728636)
Timeframe: Incision to skin closure (approximately 10 hours)
| Intervention | Milliliters (Mean) |
|---|---|
| Tranexamic Acid | 1550 |
| Placebo | 1600 |
Number of participants who experienced arterial or venous thromboembolism, neurologic complications (including stroke, seizure,and delirium), infections, and pulmonary renal or cardiac adverse outcomes (demand ischemia, myocardial infarction or new arrhythmia) before another operative procedure or hospital discharge. (NCT01728636)
Timeframe: Time of surgery to date of discharge from hospital (average 7 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 9 |
| Placebo | 9 |
Total operating room time from incision to closure of incision in minutes. (NCT01728636)
Timeframe: Minutes
| Intervention | Minutes (Median) |
|---|---|
| Tranexamic Acid | 602 |
| Placebo | 576 |
Total red blood cells transfused in the intraoperative period in (mL). Total RBC equal packed red blood cells and cell saver infusion. (NCT01728636)
Timeframe: Intraoperative period (approximately 12 hours)
| Intervention | milliliters (Median) |
|---|---|
| Tranexamic Acid | 1140 |
| Placebo | 1460 |
Total milligrams of intravenous tranexamic acid administered during the surgical procedure. (NCT01728636)
Timeframe: Intraoperative period
| Intervention | milligrams (Median) |
|---|---|
| Tranexamic Acid | 1408 |
| Placebo | 0 |
Measured in Days (NCT03825939)
Timeframe: At Hospital Discharge
| Intervention | Days (Mean) |
|---|---|
| Intravenous Tranexamic Acid | 3 |
| Intravenous Placebo | 3 |
| Intravenous Tranexamic Acid Followed by Intravenous Placebo | 3 |
Study patients received 100 mg of intravenous hydrocortisone 2 h prior to surgery, and controls received normal saline. Blood samples, drawn pre-incision and at 4 h post tourniquet release, were assayed for PF1.2 and PAP (NCT01815918)
Timeframe: Baseline and up to 4 hours following surgery
| Intervention | ug/L (Mean) | |
|---|---|---|
| Baseline | 4 hs | |
| Placebo | 623.3 | 1086.8 |
| Treatment | 808.4 | 1638.6 |
Study patients received 100 mg of intravenous hydrocortisone 2 h prior to surgery, and controls received normal saline. Blood samples, drawn pre-incision and at 4 h post tourniquet release, were assayed for PF1.2 and PAP (NCT01815918)
Timeframe: Baseline and up to 4 hours following surgery
| Intervention | pMol/L (Mean) | |
|---|---|---|
| Baseline | 4s | |
| Placebo | 263.6 | 935.8 |
| Treatment | 266.5 | 615.9 |
9 reviews available for tranexamic acid and Myocardial Infarction
| Article | Year |
|---|---|
Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint replacement for hip, pelvic and long bone fractures.
Topics: Arthroplasty, Replacement; Fibrinogen; Fractures, Bone; Hemorrhage; Hemostatics; Humans; Myocardial | 2023 |
Prophylactic intravenous tranexamic acid and thromboembolism in non-cardiac surgery: a systematic review, meta-analysis and trial sequential analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Thr | 2023 |
Acute Myocardial Infarction After Tranexamic Acid: Review of Published Case Reports.
Topics: Adult; Aged; Blood Loss, Surgical; Female; Humans; Male; Middle Aged; Myocardial Infarction; Risk Fa | 2020 |
Intravenous versus topical tranexamic acid in primary total hip replacement: A systemic review and meta-analysis.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2016 |
The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Coronary Artery | 2009 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network meta-analysis of randomised and observational studies.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2012 |
Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints.
Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Cardiac | 1999 |
Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints.
Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Cardiac | 1999 |
Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints.
Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Cardiac | 1999 |
Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints.
Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Cardiac | 1999 |
Clinical application of inhibitors of fibrinolysis.
Topics: 4-Aminobenzoic Acid; Aminocaproic Acid; Angioedema; Antifibrinolytic Agents; Aprotinin; Blood Preser | 1985 |
5 trials available for tranexamic acid and Myocardial Infarction
| Article | Year |
|---|---|
Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial.
Topics: Acute Disease; Adult; Aged; Antifibrinolytic Agents; Case-Control Studies; Double-Blind Method; Fema | 2020 |
Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial.
Topics: Acute Disease; Adult; Aged; Antifibrinolytic Agents; Case-Control Studies; Double-Blind Method; Fema | 2020 |
Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial.
Topics: Acute Disease; Adult; Aged; Antifibrinolytic Agents; Case-Control Studies; Double-Blind Method; Fema | 2020 |
Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial.
Topics: Acute Disease; Adult; Aged; Antifibrinolytic Agents; Case-Control Studies; Double-Blind Method; Fema | 2020 |
Aspirin in coronary artery surgery: 1-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery trial.
Topics: Aged; Antifibrinolytic Agents; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Coronary Th | 2019 |
Tranexamic acid in coronary artery surgery: One-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial.
Topics: Activities of Daily Living; Aged; Antifibrinolytic Agents; Aspirin; Coronary Artery Bypass; Coronary | 2019 |
Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Aprotinin; Blood Coagulation; Bloo | 2008 |
Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Aprotinin; Blood Coagulation; Bloo | 2008 |
Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Aprotinin; Blood Coagulation; Bloo | 2008 |
Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Aprotinin; Blood Coagulation; Bloo | 2008 |
Tranexamic acid (Cyklokapron) is not necessary to reduce blood loss after coronary artery bypass operations.
Topics: Adult; Aged; Blood Transfusion, Autologous; Body Surface Area; Coronary Artery Bypass; Early Ambulat | 1993 |
17 other studies available for tranexamic acid and Myocardial Infarction
| Article | Year |
|---|---|
No Difference in Blood Loss and Risk of Transfusion Between Patients Treated with One or Two Doses of Intravenous Tranexamic Acid After Simultaneous Bilateral TKA.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2022 |
Tranexamic acid and perioperative myocardial infarction: a retrospective database analysis.
Topics: Antifibrinolytic Agents; Databases, Factual; Humans; Myocardial Infarction; Retrospective Studies; T | 2022 |
Tranexamic Acid Use During Surgery Associated with Extension of Acute Perioperative Type 1 Myocardial Infarction: A Case Report.
Topics: Aged; Biomarkers; Female; Femoral Artery; Humans; Myocardial Infarction; Thrombosis; Tranexamic Acid | 2022 |
Tranexamic Acid Is Safe in Patients with a History of Coronary Artery Disease Undergoing Total Joint Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2021 |
Acute MI in a young hypertensive woman: could it be due to tranexamic acid?
Topics: Adult; Antifibrinolytic Agents; Diagnosis, Differential; Female; Humans; Hypertension; Myocardial In | 2013 |
Scientific letter: could tranexamic acid use in surgery reduce perioperative myocardial infarction?
Topics: Antifibrinolytic Agents; Humans; Intraoperative Complications; Multicenter Studies as Topic; Myocard | 2013 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Association between CK-MB Area Under the Curve and Tranexamic Acid Utilization in Patients Undergoing Coronary Artery Bypass Surgery.
Topics: Aged; Antifibrinolytic Agents; Area Under Curve; Blood Loss, Surgical; Coronary Artery Bypass; Creat | 2017 |
Orbital subperiosteal hematoma after thrombolysis and anticoagulation for acute myocardial infarction.
Topics: Accidental Falls; Acute Disease; Adult; Anticoagulants; Antifibrinolytic Agents; Craniocerebral Trau | 2009 |
Acute myocardial infarction in a patient with hemophilia A and factor V Leiden mutation.
Topics: Angioplasty, Balloon, Coronary; Antifibrinolytic Agents; Blood Loss, Surgical; Coagulants; Coronary | 2009 |
Combined treatment with tranexamic acid and oral contraceptive pill causes coronary ulcerated plaque and acute myocardial infarction.
Topics: Adult; Chest Pain; Contraceptives, Oral; Coronary Angiography; Coronary Vessels; Drug Therapy, Combi | 2004 |
The risk associated with aprotinin in cardiac surgery.
Topics: Adult; Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Pr | 2006 |
The risk associated with aprotinin in cardiac surgery.
Topics: Adult; Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Pr | 2006 |
The risk associated with aprotinin in cardiac surgery.
Topics: Adult; Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Pr | 2006 |
The risk associated with aprotinin in cardiac surgery.
Topics: Adult; Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Pr | 2006 |
Acute myocardial infarction following tranexamic acid use in a low cardiovascular risk setting.
Topics: Adult; Antifibrinolytic Agents; Female; Humans; Myocardial Infarction; Postoperative Care; Tranexami | 2008 |
Cardiopulmonary by-pass in a patient with acquired C1 inhibitor deficiency.
Topics: Aged; Anabolic Agents; Angioedema; Antifibrinolytic Agents; Aprotinin; Autoimmune Diseases; Calcium | 1997 |
A new vascular sealant (Sealgel) to achieve rapid hemostasis after percutaneous angioplasty in anticoagulated patients: clinical feasibility and preliminary results.
Topics: Aged; Ancrod; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Anticoagul | 2001 |
Is tranexamic acid safe in patients undergoing coronary endarterectomy?
Topics: Aged; Coronary Artery Bypass; Coronary Artery Disease; Endarterectomy; Female; Graft Occlusion, Vasc | 2001 |
Acute myocardial infarction after oral tranexamic acid treatment initiation.
Topics: Administration, Oral; Aged; Female; Hemorrhage; Humans; Myocardial Infarction; Tranexamic Acid | 2002 |